<DOC>
	<DOCNO>NCT00622622</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immune response different dose VEGFR2-169 emulsify Montanide ISA 51 combination gemcitabine determine recommend phase II dose .</brief_summary>
	<brief_title>Gemcitabine With Antiangiogenic Peptide Vaccine Therapy Patients With Pancreatic Cancer</brief_title>
	<detailed_description>Vascular endothelial growth factor receptor 2 ( VEGFR2 ) essential target tumor angiogenesis , VEGFR2-169 induces specific Cytotoxic T lymphocytes ( CTL ) VEGFR2 express target . VEGFR2-169 show strong anti-tumor effect restrict HLA-A*2402 vitro , peptide induces CTL cancer patient . 60 % Japanese population HLA-A*2402 . VEGFR2-169 suitable clinical trial , gemcitabine approve pancreatic cancer . Gemcitabine report improve immune-response , therefore synergistic effect vaccine therapy chemotherapy expect . In clinical trial , evaluate safety , tolerability immune response different dose VEGFR2-169 emulsify Montanide ISA 51 combination gemcitabine determine recommend phase II dose peptide .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1. locally advanced metastatic pancreatic cancer preclude curative surgical resection recurrent pancreatic cancer 2. measurable disease CT scan PATIENT CHARACTERISTICS 1 . ECOG performance status 02 2 . Life expectancy &gt; 3 month 3 . Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 75000/mm3 Bilirubin &lt; 3.0 mg/dl Aspartate transaminase &lt; 150 IU/L Alanine transaminase &lt; 150 IU/L Creatinine &lt; 3.0 mg/dl 4 . HLAA*2402 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Active uncontrolled infection 4 . Concurrent treatment steroid immunosuppressing agent 5 . Prior chemotherapy gemcitabine 6 . Prior chemotherapy , radiation therapy , immunotherapy within 4 week 7 . Serious nonhealing wound , ulcer , bone fracture 8 . Active uncontrolled malignancy 9 . Ileus 10 . Interstitial pneumonia 11 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>